RxDoctor Payments DataLook up a doctor →

Danielle Castillo, MD

Endocrinology, Diabetes & Metabolism · Chesapeake, VANPI 1457512667

Payments from drug & device makers

$10,737in general payments, 2019–2025

Across 596 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Corcept Therapeutics$767
  • Amgen$711
  • Radius Health, Inc.$630
  • Xeris Pharmaceuticals, Inc.$521
  • plus $6K from 40 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC85$1,369
Novo Nordisk106$1,209
Corcept Therapeutics31$767
Amgen(2 entities)37$711
Radius Health, Inc.28$630
Xeris Pharmaceuticals, Inc.27$521
Boehringer Ingelheim26$478
Bayer26$465
Sanofi-aventis U.S. LLC19$400
Mannkind Corporation22$398
Dexcom, Inc.21$327
Insulet Corporation18$319
AstraZeneca(2 entities)6$276
AbbVie17$264
Merck21$239
Abbott11$230
Medtronic(2 entities)6$209
Pfizer9$197
Ascendis Pharma Endocrinology Inc10$176
Cequr Corporation3$159
Lifescan, Inc.5$146
Recordati_rare_diseases_inc.6$118
IBSA Pharma Inc.5$114
Ultragenyx Pharmaceutical Inc.5$108
Amarin Pharma, Inc.5$94
BETA Bionics, Inc.7$88
Kyowa Kirin, Inc.4$88
Amneal Pharmaceuticals LLC4$71
Tandem Diabetes Care, Inc.3$61
Sequel Med Tech, LLC2$53
Amphastar Pharmaceuticals, Inc.1$49
Endo USA, Inc.2$46
EUSA Pharma (US) LLC2$45
Zealand Pharma US, Inc.2$39
Shire North American Group Inc2$30
Johnson & Johnson2$30
Vistapharm, Inc.1$28
Neurocrine Biosciences, Inc.1$28
Senseonics, Incorporated1$26
Novartis1$22
Amryt Pharma Holdings Ltd1$21
Takeda Pharmaceuticals U.S.A., Inc.1$20
Acorda Therapeutics, Inc1$18
Acella Pharmaceuticals, LLC1$18
UCB, Inc.1$16
Tolmar, Inc.1$13

How this compares

$10,737 in reported general payments places this provider in the 80th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.

See all endocrinology, diabetes & metabolism providers in Virginia →

Medicare billing

Part B allowed, 2024
$301,355
Medicare patients
446
Services billed
14,788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Chesapeake

See the full list for Virginia →

Where these figures come from

Is this you, or does something look wrong? →